| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 0 | 0 | 10 | 790 |
| Sales Growth | unch | unch | -100.00% | -98.73% | -53.80% |
| Net Income | -14,790 | -24,730 | -18,660 | -12,810 | -18,950 |
| Net Income Growth | +40.19% | -32.53% | -45.67% | +32.40% | -13.61% |
Molecular Partners Ag ADR (MOLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as DARPin(R) therapeutics. Molecular Partners AG is based in SWITZERLAND.
Fiscal Year End Date: 12/31